Please login to the form below

Not currently logged in
Email:
Password:

neuroscience

This page shows the latest neuroscience news and features for those working in and with pharma, biotech and healthcare.

Takeda to sell Japan consumer health unit for $2.3bn

Takeda to sell Japan consumer health unit for $2.3bn

This includes gastroenterology, rare disease, plasma-derived therapies, oncology and neuroscience, five therapy areas which the Japanese pharma company said are core to its global long-term growth.

Latest news

More from news
Approximately 13 fully matching, plus 175 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    MindMaze, the Swiss start-up which entered the unicorn club in 2016, works at the intersection of neuroscience, mixed reality and artificial intelligence and builds intuitive human machine interfaces for different

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    The reactions to Pfizer dropping neuroscience research ranged from ‘disappointing’ to ‘demoralising’.The move was compounded by the company saying the decision was driven by science rather than cost, a shockwave ... It’s snakes and ladders.

  • AI and genomics: a revolution in drug discovery and development AI and genomics: a revolution in drug discovery and development

    Ten of the new ALS-related genes are being tested using an existing neural progenitor cell assay at the Sheffield Institute for Translational Neuroscience (SITraN).

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    In 2018, venture capitalists invested almost $1.5bn (1.4bn) in neuroscience biotechs, an increase of more than 500% over funding levels in 2011. ... Dave Reese, head of R&D at Amgen, touched on those issues to explain Amgen’s exit from neuroscience

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    the phases of development represented in the analysis and, until the recent about-turn by Biogen, the outlook for neuroscience was bleak. ... Therapeutically, oncology and rare diseases will likely remain attractive candidates for investment, while

More from intelligence
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 7 fully matching, plus 20 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics